Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny subsequently
Immigrated to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II
Trial publication.

After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published anumber of experimental research papers and theoretical articles as sole
Writer. Those sole-author publications
Included two crucial topics.
The first of these mentioned selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Verifying their resistance. The results and underlying
Notion were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.

The second topic throughout Dr. Blagosklonny’s sole-author articles
Is a research methodology to produce knowledge by
Bringing a few facts together from seemingly unrelated fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important result revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others cannot even see. ”

In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.

Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Preventing body aging — in other words, “preventing cancer
Via staying young. ” His lab closely collaborated with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Medicines beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.

Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging medicines to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
https://www.roswellpark.org/mikhail-blagosklonny
https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.9.8899
https://tandfonline.com/doi/abs/10.4161/cbt.8.9.8899